IRD Invest: virtual investor conference, 29 July 2020
Thanks to all those presenters and investors who made time to attend IRD Invest, IR Department’s virtual investor conference on 29 July 2020.
Replays of the presentations are available via the links below.
Dr James Garner, CEO & Executive Director, Kazia Therapeutics Limited (ASX: KZA)
Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Its lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.
John Kelly, Founder, Managing Director & CEO, Atomo Diagnostics Limited (ASX: AT1)
Atomo is a medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Its patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers.
Dr Tim Oldham, CEO and Managing Director, AdAlta Limited (ASX: 1AD)
AdAlta is a Melbourne-based clinical stage biotechnology company using its i-body platform to discover and develop next generation protein therapeutics addressing drug targets that are challenging for other technologies.
Dr Daniel Tillett, COO, Race Oncology Limited (ASX: RAC)
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later stage drug assets, principally in the cancer field. It has a Phase II/III cancer drug called Bisantrene which it is developing for acute myeloid leukaemia (AML) as well as breast and ovarian cancer.
28 July 2020: Atomo & Access Bio enter North American COVID-19 partnership
23 July 2020: First participants dosed in AdAlta's AD-214 Phase I clinical trial
22 July 2020: Race Oncology secures fourth patent for bisantene
22 July 2020: Kazia calls for greater awareness of one of the deadliest brain cancers
15 July 2020: Race Oncology investor update
14 July 2020: AFR article: Sector outperformance set to continue for a long time
13 July 2020: Race Oncology announces strategic investment from prominent biotech investors
22 June 2020: Kazia presents interim paxalisib data at AACR
11 June 2020: AdAlta CEO, Dr Tim Oldham discusses importance of becoming a clinical company